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A Multi-target Small Molecule for Targeted Transcriptional
Activation of Therapeutically Significant Nervous System
Genes
Yulei Wei,[a] Ganesh N. Pandian,[b] Tingting Zou,[a] Junichi Taniguchi,[a] Shinsuke Sato,[b] Gengo Kashiwazaki,[a]
Thangavel Vaijayanthi,[a] Takuya Hidaka,[a] Toshikazu Bando,[a] and Hiroshi Sugiyama*[a, b]
An integrated multi-target small molecule capable of altering
dynamic epigenetic and transcription programs associated
with the brain and nervous system has versatile applications in
the regulation of therapeutic and cell-fate genes. Recently, we
have been constructing targeted epigenetic ON switches by in-
tegrating sequence-specific DNA binding pyrrole-imidazole
polyamides with a potent histone deacetylase inhibitor SAHA.
Here, we identified a DNA-based epigenetic ON switch termed
SAHA-L as the first-ever multi-target small molecule capable of
inducing transcription programs associated with the human
neural system and brain synapses networks in BJ human fore-
skin fibroblasts and 201B7-iPS cells. Ingenuity pathway analysis
showed that SAHA-L activates the signaling of synaptic recep-
tors like glutamate and g-aminobutyric acid, which are key
components of autism spectrum disorders. The long-term incu-
bation of SAHA-L in 201B7-iPS cells induced morphology
changes and promoted a neural progenitor state. Our finding
suggests that the tunable SAHA-L could be advanced as a cell-
type-independent multi-target small molecule for therapeutic
and/or cell-fate gene modulation.
The brain and nervous system functions involve precise or-
chestration of diverse bioactive factors, intricate receptor sig-
naling, and alteration in epigenetic programs.[1] Therefore, de-
fective modifications in the intertwined brain synapses and
neurotransmitter networks are difficult to repair.[2] Epigenetic
cell-fate regulation often supersedes the local microenviron-
mental cues.[3] Mainly, histone deacetylase (HDAC)-governed
acetylation and deacetylation of histone proteins play a critical
role in neural fate decisions by changing the accessibility of
DNA towards transcription factors (TFs).[4] Several HDAC inhibi-
tors, including valproic acid and sodium butyrate, have been
shown to promote transcription associated with neuronal dif-
ferentiate and brain development.[5] Besides, reversal of histone
deacetylation could also promote differentiation of human plu-
ripotent stem cells (hPSCs) towards neural progenitor cells
(NPCs).[6] SAHA is known to enhance neuronal differentiation/
regeneration and is particularly attractive, as it is the most
common HDAC inhibitor already approved by the FDA for
therapeutic applications.[7]
However, lack of gene specificity and tunable targeting effi-
cacy is a major shortcoming of SAHA as a potential drug to
treat the pathological nervous system. Also, there is a need to
employ multiple small molecules specific for individual signal-
ing pathways and factors. However, for clinical translation,
fewer factors need to be used.[8]
Considering the exponential increase in the number of an-
notated brain synapses and neurotransmitter genes, there is
an increasing need to develop an epigenetically active multi-
target synthetic strategy that mimics the structural simplicity
and functional efficacy of natural TFs .[9] Hairpin pyrrole-imida-
zole polyamides (PIPs) represent a class of DNA minor-groove-
binding small molecules that specifically recognize each of the
four Watson–Crick base pairs.[10] Distinct PIPs were conjugated
with alkylating agents to attain dual-functional OFF switches
for different cancer-associated genes that closely mimicked the
natural TFs in terms of structure and repressive function.[11] As
a novel chemical approach to activate the specific gene of in-
terest, recently, we integrated HDAC inhibitor SAHA with PIPs
to create a new type of synthetic TFs called SAHA-PIPs. We
first created a library of 16 SAHA-PIPs with unique chemical ar-
chitectures and named them alphabetically from “A” to “P”.[12]
Likewise, we constructed a different set of 16 SAHA-PIPs
termed “Q” to “F” and identified hit SAHA-PIPs with bioactivity
towards pluripotency genes.[13] Through independent lines of
evidence, we have previously shown that distinct SAHA-PIPs
could modulate epigenetic programs at distinct DNA sequen-
ces to induce selective genes and noncoding RNAs.[14] Stem
cell scientists prefer human dermal fibroblasts (HDFs) as the
cell source for cellular reprogramming, as fibroblasts are readily
available and can be acquired in a non-invasive manner.
Hence, we evaluated the effect of constructed SAHA-PIPs on
genome-wide gene expression in HDF cells and identified cer-
tain SAHA-PIPs as ON switches for germ-cell, stem-cell, and ret-
inal-cell genes,[15] However, the effect of SAHA-PIP was con-
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fined to gene expression analysis. Also, it was unclear whether
SAHA-PIP could retain bioactivity on pluripotent cell types and
direct them to specific cell differentiation.
Herein, through functional gene expression analysis in BJ
human foreskin fibroblasts, we identified the first multi-target
ON switch SAHA-L (Figure 1) for multiple genes associated
with the brain synapses and neurotransmitter networks. Fur-
thermore, we evaluated the effect of SAHA-L on 201B7 iPS
cells to validate whether SAHA-L could retain the bioactivity
and induce neural progenitor markers like NESTIN, PAX 6, and
NGN2.
Initially, we carried out gene ontology studies of preliminary
microarray data in 54 year-old breast HDFs, which indicated
that SAHA-L could activate few Wnt/b-catenin signaling-regu-
lated neural genes (see Figure S1 in the Supporting Informa-
tion). However, the effect was not remarkable. As BJ foreskin fi-
broblasts are more amenable to reprogramming, we carried
out further studies in this cell line by using purified SAHA-L
and l- bbAc lacking the SAHA moiety as the control (Fig-
ure S2). Initial standardization studies suggested that 1 mm
treatment for 48 h as the optimal condition for attaining regu-
lar gene induction activity. Subsequently, the whole transcrip-
tional gene profile of BJ fibroblasts was performed by
a human gene 2.1 ST array strip after treatment with DMSO, l-
bbAc (1 mm), and SAHA-L (1 mm), respectively, over 48 h. The in-
itial microarray data were annotated by using the expression
console and the transcriptome analysis console V2.0. The result
showed that SAHA-L exhibited increased bioactivity in BJ fibro-
blasts compared to HDFs and about 1470 genes were signifi-
cantly upregulated compared with that in DMSO (Fold
Change>2 and ANOVA p-value<0.05). QIAGEN’s ingenuity
pathway analysis (IPA) of the up-regulated genes showed that,
in SAHA-L-treated BJ fibroblasts, the top five networks are re-
markably related to 1) cell-to-cell signaling and interaction and
2) nervous system development and function (Table S1). A
gene ontology study clearly substantiated that SAHA-L-in-
duced genes (10/15, green bars) are associated with neuro-
transmitter signaling and neuronal development (Figure 2A).
GABAergic and glutamatergic synapse balance are associat-
ed with cerebral dysfunction, especially in autism spectrum dis-
orders. GABA receptors play a vital role in excitatory-inhibited
features of the brain, and autistic subjects were shown to have
reduced GABAB receptor 1 (GABBR1) and GABAB receptor 2
(GABBR2) in their brain.[16] Interestingly, these two factors were
upregulated in SAHA-L-treated BJ fibroblasts (Figure 2B). Fur-
thermore, SAHA-L also had a multi-target capability to modu-
late the GABA and glutamate receptor signaling processes,
Figure 1. Chemical structure of the i) hit SAHA-PIP L or SAHA-L encompass-
ing the PIP targeting 5’-WGGGW-3’ (W=A/T) and epigenetically active
SAHA, and ii) L-bbAc, the control PIP lacking SAHA moiety.
Figure 2. A) Top 15 canonical pathways of SAHA-L-treated BJ fibroblasts
gene change (Fold Change>2 and ANOVA p-value <0.05) compared with
DMSO. Green bars show the neural system-related pathways. B) Heat map of
selected neural related gene expression of DMSO, l-bbAc, and SAHA-L-treat-
ed HDFs. The blanket in the right is the related gene symbol of the hot
map.
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which are known to be associated with all neurotransmitter-re-
lated defects.[17] Besides, the CREB (cAMP response element
binding protein) is a TF that works not only in cell proliferation,
differentiation, and process outgrowth, but also in brain activi-
ty such as learning, memory, and plasticity.[18] Therefore, chemi-
cal control of CREB signaling could have an influence on the
whole-brain functional network.
Accordingly, in-depth analysis of the upregulated nervous
system genes showed that up to 128 and 103 genes were re-
lated to neuron development and synaptic transmission, re-
spectively (Table S2). The heat map of the compiled primary
neural system related genes clearly showed that the therapeut-
ically important genes, including CNTNAP2, NRXN1, and others
(Figure 2B), were notably increased in SAHA-L and not in
DMSO- or l-bbAc-treated BJ fibroblasts. Analysis of genetic in-
teractions by using GENEMANIA showed that the up-regulated
genes have a significant connection with each other (Fig-
ure S3) and the common gene network associated with the
central nervous system.[19] Collectively, the functional analysis
of SAHA-L-upregulated genes validates the remarkable activa-
tion of selective transcripts associated human neural system
and brain synapses neurotransmitter signaling. It is important
to note here that neither l-bbAc lacking SAHA nor SAHA alone
had the bioefficacy of SAHA-L. According to our previous re-
ports,[14] alteration of acetylation status at specific gene loci
corresponding to the key binding 5‘-WWGGGW-3‘ sequence of
the PIP is considered to be the mechanism behind the unusual
domino effect like multiple gene-activating capability displayed
by SAHA-L.
Although SAHA-L was shown to have a remarkable effect on
the fibroblasts, where the developmental genes are epigeneti-
cally silenced, their effect on human pluripotent stem cell
(PSC) lines and whether they retain their bioactivity in PSCs
was unknown. As SAHA-L operates by binding specific DNA se-
quences and altering the local chromatin architecture, they are
expected to have similar bioefficacy in different cell types. To
this end, we evaluated the effect SAHA-L in human-induced
pluripotency stem cells (201B7 iPS cells) along with the con-
trols DMSO and l-bbAc. Based on the initial optimization stud-
ies, we found 10 mm and 96 h as the optimal treatment condi-
tions. Microarray analysis and subsequent comparative studies
of SAHA-L versus DMSO showed that, among the top 50 upre-
gulated genes, 19 genes were common in both 201B7 iPS cells
and BJ fibroblasts (Figure 3A). Gene ontology analysis showed
that the identical genes belonged to nervous system develop-
ment and synaptic receptor signaling. As canonical pathway
analysis indicated synaptic formation as the top pathway, we
carried out real-time PCR analysis of the key therapeutic genes
including CNTNAP2, REELIN, NOS1AP, KALIRIN, DISC1, and
NRXN1 after SAHA-L treatment to both 201B7-iPS cells and BJ
fibroblasts (Figure 3B–I). In agreement with the microarray re-
sults, SAHA-L, and not the control DMSO, significantly (P<0.05
or P<0.01) induced the endogenous expression of CNTNAP2,
NOS1AP, REELIN, and KALIRIN in BJ fibroblasts (Figure 3B–E)
and 201B7-iPS cells (Figure 3F–I).
The absence of CNTNAP2 is known to be responsible for
neuronal migration and core autism-related deficits.[20] Like-
wise, DISC and REELIN are also associated with autism-spec-
trum disorders like schizophrenia.[21] Although SAHA-L did not
have a significant effect on the endogenous expression of
DISC1 and NRXN1, the effect was still notable (Figure S4). Pluri-
potent stem cells and BJ fibroblasts have distinct global epige-
nome profiles and the acetylation status to govern the devel-
opmental genes is noticeably different in these two cell
lines.[22] Hence, despite the similar significance, the fold induc-
tion level of the key synaptic receptor signaling genes in
SAHA-L-treated cells was comparatively lower in 201B7-iPS
cells with respect to BJ fibroblasts (Figure 3B–I). Nevertheless,
real-time PCR analysis clearly demonstrates that SAHA-L could
remarkably induce the endogenous expression of synaptic re-
ceptor signaling genes in both iPS cells and BJ fibroblasts. To
evaluate if the bioactivity of SAHA-L could be retained when
treated, not as conjugates, but as individual parts, we treated
SAHA and PIP (l-bbAc) individually or together in trans. Q-RT-
PCR data showed the importance of SAHA-L as conjugates, as
no significant effect could be observed on the endogenous
Figure 3. Gene expression in BJ fibroblasts and 201B7-iPS cells. A) The
common gene numbers of the top 50 genes altered by SAHA-L in BJ fibro-
blasts and 201B7-iPS cells (P<0.05). Quantitative real-time PCR analysis of
B) KALIRIN C) CNTNAP2, D) REELIN, E) NOS1AP in BJ fibroblasts and F) KALIR-
IN G) CNTNAP2, H) REELIN, I) NOS1AP in 201B7 iPS cells. The relative gene
expression was normalized to the house-keeping gene b-ACTIN. Three bio-
logical replicates were performed and the means:SD are indicated;
*p<0.05, **p<0.01.
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gene expression of any of the key brain or nervous system
genes in both BJ fibroblasts and 201B7-iPS cells (Figures S5A
and S5B). Also, we tested the bioactivity of a control PIP-
SAHA conjugate called SAHA-K, where the PIP structure was al-
tered to recognize the 5’-WGGWWW-3’ (W=A/T) sequence.
SAHA-K, known to selectively activate germ cell genes,[15] did
not induce synaptic genes (Figures S5C and S5D) to suggest
the importance of DNA binding specificity.
As SAHA-L induced a large number of neurodevelopmental
genes, we tested whether continuous treatment of SAHA-L
could direct the differentiation of iPS cells into specific neural
cell types. For this, we employed MEF-conditional medium
without b-FGF and continuously treated the previously em-
ployed effectors in iPS cells. As expected, SAHA-L, and not the
controls (DMSO and l-bbAc), induced relatively significant mor-
phology changes. Marker analysis using real-time PCR showed
a significant (P<0.01) increase in the endogenous expression
of essential neural cell factors like NESTIN, PAX6, and NGN2
(Figure 4A–C). Also, SOX9 expression was suppressed with
SAHA-L treatment (Figure S6A). It is important to note that re-
pression of SOX9 is known to induce neurogenesis.[15] Howev-
er, SAHA-L treatment has little effect on the mature neuronal
gene markers MAP 2 and GDNF (Figures S6B and S6C) when
compared to DMSO treatment. We then subjected the effec-
tor-treated cells cultured for 15 days to immunostaining. Micro-
scopic studies showed nestin-positive cells in SAHA-L-treated
cells and not in the cells treated with the control (Figure 4D–I).
Despite the alteration in treatment conditions, such as incuba-
tion time, concentration, and mode of employment, SAHA-L
did not induce the matured neural cell type. Nevertheless, the
long-term incubation of SAHA-L in iPS cells shifted the tran-
scriptional program from a pluripotent state to a neural pro-
genitor state.
Recently, genetic knowledge-based targeting of small mole-
cules has been gaining increasing importance in therapeutic
and cell-fate gene modulation. Advanced omic and bioinfor-
matic tools have been revealing the role of multi-gene net-
work and complex signaling processes in the pathological
nervous system. To achieve the precise orchestration observed
in the natural cellular environment, there is a need to target
multiple factors. But, for clinical translation, synthetic small
molecules and the employment of fewer factors are preferred.
Until now, no single small molecule has been known to trigger
the transcriptional activation of multiple synaptic receptors like
glutamate and g-aminobutyric acid, which are key components
of autism spectrum disorders. This is the first report that dem-
onstrates the bioefficacy of a DNA-based epigenetically active
multi-target small molecule to trigger the transcriptional acti-
vation of brain synapses and neurotransmitter networks in
both human fibroblasts and a PSC line. Such similar bioactivity
of SAHA-L in a somatic and a pluripotent cell type, in contrast
to SAHA, suggests the critical role of PIPs in directing them to
a key consensus motif. At this moment, it is difficult to identify
and annotate the actual mechanism and binding motif of
SAHA-L leading to the selective activation of nervous system
and brain associated genes. However, analysis of binding sites
and functional gene expression has shown that SAHA-L shares
about six corresponding binding sites with the ZPF521 (Fig-
ure S7). As zinc-finger TFs, like ZFP-521, are known to repro-
gram HDFs into stable self-renewing neural stem cells,[23] it is
possible that SAHA-L mimics the function of ZFP-521 to acti-
vate neural and brain-associated genes. Nevertheless, the re-
markable activity of a single dual-functional small molecule like
SAHA-L to activate the intricate synaptic receptor and brain
development genes suggests the possibility of advancing
them as brain-cell gene switches.
Although SAHA-L induced neural progenitor program in
201B7-iPS cells, the bioactivity was relatively small. However,
the tunability of PIP conjugates offers the prospect of advanc-
ing them to coax pluripotent stem cells in a step-wise manner
and attain the desired neural cell types. This proof-of-concept
study, showing the similar bioactivity of SAHA-L in entirely dif-
ferent cell lines, suggests their potential use as transgene-free
tools for both stem cell differentiation and transdifferentiation.
Complex neurological disorders including autism and schizo-
phrenia often involve dysregulated synaptic receptor signaling.
As SAHA-L is capable of activating critical genes known to sup-
press nervous system disorders, their derivatives could be de-
veloped as targeting small molecules to regulate therapeutical-
ly important synapse gene(s) of interest. Advancing this syn-
thetic epigenetic program-editing strategy could be useful in
developing multiple variants of clinically useful bioactive li-
gands.
Experimental details are shown in the Supporting
Information.
Figure 4. Characterization of neurogenesis in human-induced pluripotent
cells : The expression of several neural progenitor specific markers :
A) NESTIN, B) PAX 6, C) NGN2 are displayed, as determined by q-RT-PCR anal-
ysis. The relative gene expression was normalized to the house-keeping
gene b-ACTIN, Three biological replicates were performed and the
means:SD are indicated; *p<0.05, **p<0.01. D–I: The immunostaining of
neural progenitor marker NESTIN was analyzed 15 d after SAHA-L treatment.
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